NATIONAL INSTITUTES OF HEALTH
- Country
- πΊπΈUnited States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Clinical Trials
4.1k
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3413 trials with phase data)β’ Click on a phase to view related trials
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
- Conditions
- Recurrent Endometrial CarcinomaAdvanced Endometrial Carcinoma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Magnetic Resonance Imaging
- First Posted Date
- 2025-09-30
- Last Posted Date
- 2025-10-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 255
- Registration Number
- NCT07198074
Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
- Conditions
- Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Locally Recurrent Head and Neck Squamous Cell CarcinomaLocally Recurrent Hypopharyngeal Squamous Cell CarcinomaLocally Recurrent Laryngeal Squamous Cell CarcinomaLocally Recurrent Oral Cavity Squamous Cell CarcinomaStage III Lip and Oral Cavity Cancer AJCC v8Locally Recurrent Oropharyngeal Squamous Cell CarcinomaStage II Laryngeal Cancer AJCC v8Stage II Lip and Oral Cavity Cancer AJCC v8
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Positron Emission TomographyRadiation: Radiation TherapyProcedure: Salvage Surgery
- First Posted Date
- 2025-09-29
- Last Posted Date
- 2025-10-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 180
- Registration Number
- NCT07195734
Hepatic Lipid Metabolism-Alcohol Use Disorder
- Conditions
- Alcohol Use Disorder
- First Posted Date
- 2025-09-25
- Last Posted Date
- 2025-09-29
- Target Recruit Count
- 25
- Registration Number
- NCT07191561
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Testing the SurVaxM Vaccine for Lung Cancer Prevention
- Conditions
- Lung Carcinoma
- Interventions
- Procedure: Biospecimen CollectionOther: Questionnaire Administration
- First Posted Date
- 2025-09-12
- Last Posted Date
- 2025-09-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 80
- Registration Number
- NCT07169617
- Locations
- πΊπΈ
Rocky Mountain Regional VA Medical Center, Aurora, Colorado, United States
πΊπΈNorthwestern University, Chicago, Illinois, United States
πΊπΈRoswell Park Cancer Institute, Buffalo, New York, United States
Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation
- Conditions
- Hematologic MalignanciesHematologic Neoplasms
- Interventions
- Biological: mCD19-CAR-CD28-CD3-zeta.(anti-CD19 CAR) retroviral vector-transduced allogeneic peripheral blood lymphocytes (PBL)Device: CD19 Flow Cytometry AssayDevice: CD19 Immunohistochemical AssayRadiation: Total Body Irradiation
- First Posted Date
- 2025-09-09
- Last Posted Date
- 2025-10-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 155
- Registration Number
- NCT07162038
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 810
- Next
News
TruDiagnostic Receives NIH Grant to Develop Revolutionary Epigenetic Disease Prediction Platform
TruDiagnostic has been awarded a competitive NIH SBIR grant to develop the W-Function Epigenomic Roadmap, a breakthrough technology that maps DNA methylation changes over time to predict chronic diseases.
Wisconsin Biotech Secures $1.8M NIH Grant to Advance iPSC-Based Diabetes Cure
Regenerative Medical Solutions received a $1.8 million NIH Phase II SBIR grant to advance its induced pluripotent stem cell therapy for diabetes treatment.
POP Biotechnologies Secures $2.46M NIH Grant for Novel Dual-Target Alzheimer's Immunotherapy
POP Biotechnologies received a $2.46 million NIH Phase II STTR grant to develop a mosaic active immunotherapy targeting both amyloid-beta plaques and phospho-tau tangles in Alzheimer's disease.
Wearable Heart Rate Variability Patch Reduces Substance Use by 64% in Recovery Patients
Mass General Brigham researchers demonstrated that a wearable heart rate variability biofeedback device significantly reduced substance cravings and use in early recovery patients.
FDA Halts New Drug Application Acceptance as Government Shutdown Begins
The FDA will not accept new drug applications during the government shutdown, though it can continue reviewing existing submissions funded by user fees.
Lunai Bioworks Completes Corporate Rebranding with Focus on AI-Powered Drug Discovery and Parkinson's Research
Lunai Bioworks Inc. (formerly Renovaro Inc.) officially adopted its new corporate identity on September 30, 2025, trading under ticker symbol "LNAI" following a 10:1 reverse stock split.
Anebulo Pharmaceuticals Initiates Phase I Trial of IV Selonabant as First Cannabis Toxicity Antidote
Anebulo Pharmaceuticals has begun dosing participants in a Phase I trial of intravenous selonabant, targeting acute cannabis-induced toxicity with NIDA funding support.
ClearNote Health Receives UK Regulatory Approval for Multi-Cancer Detection Tests
ClearNote Health has received United Kingdom Conformity Assessed (UKCA) marking for its Avantect multi-cancer detection test and Avantect ovarian cancer test, enabling market access in the UK.
NIH Awards $15.6 Million to Advance Research on Rare Bone and Metabolic Disorders
The National Institutes of Health has awarded Baylor College of Medicine $15.6 million to fund two rare disease research consortia over five years.
Lunai Bioworks Advances AI-Powered Parkinson's Biomarker Discovery Program for Strategic Pharma Partnerships
Lunai Bioworks has advanced its preclinical biomarker discovery program for Parkinson's Disease using its subsidiary BioSymetrics' proprietary Augusta Platform, positioning the initiative for strategic pharmaceutical partnerships.